SCHEMBL3671489

SCHEMBL3671489

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)C(=CCO)CC[C@@H]12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 8/20 0.59
NR3C2 P08235 7/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
SERPINA6 P08185 4/20 0.59
LMNA P02545 4/20 0.59
SHBG P04278 3/20 0.59
HSD17B10 Q99714 3/20 0.59
MAPT P10636 2/20 0.59
CYP3A4 P08684 2/20 0.59
NFKB1 P19838 2/20 0.59
BLM P54132 1/20 0.59
CYP2C9 P11712 1/20 0.59
TSHR P16473 1/20 0.59
SLC22A2 O15244 1/20 0.59
SLC22A1 O15245 1/20 0.59
SLC22A3 O75751 1/20 0.59
MAPK1 P28482 1/20 0.59
THPO P40225 1/20 0.59
MTOR P42345 1/20 0.59
SIGMAR1 Q99720 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6013906 1.00 HIF1A (0.59) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL11480876 1.00 HIF1A (0.59) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL9459018 1.00 HIF1A (0.59) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL30496663 1.00 HIF1A (0.59) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL3321767 0.88 SMN1; SMN2 (0.60) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL11154815 0.87 HIF1A (0.55) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL24722640 0.86 HIF1A (0.60) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL10627809 0.86 HIF1A (0.60) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL10627802 0.86 HIF1A (0.60) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA
SCHEMBL10627817 0.86 HIF1A (0.60) HIF1ANR3C2SMN1; SMN2SERPINA6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432399-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2004-06-30 EP claimed
US-20030124159-A1 Enhancing epidermal barrier development in skin UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2003-07-03 US claimed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO claimed
EP-0350488-B1 1,2-DEHYDROGENATION OF STEROIDAL 21-ESTERS WITH A. SIMPLEX THE UPJOHN COMPANY (US) 1993-09-08 EP claimed
US-4749649-A Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen THE UPJOHN COMPANY (US) 1988-06-07 US claimed
EP-0127294-B1 STEROID DEHYDROGENATION THE UPJOHN COMPANY (US) 1986-12-17 EP claimed
EP-0127294-A1 Steroid dehydrogenation THE UPJOHN COMPANY (US) 1984-12-05 EP claimed
US-10456344-B2 Hair composition CONOPCO, INC. (US) 2019-10-29 US disclosed
US-10406091-B2 Skin anti-ageing composition CONOPCO, INC. (US) 2019-09-10 US disclosed
EP-2788088-B1 SKIN ANTI-AGEING COMPOSITION UNILEVER PLC (GB) 2019-06-19 EP disclosed
US-20170360673-A1 HAIR COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2017-12-21 US disclosed
EP-2788088-A1 SKIN ANTI-AGEING COMPOSITION Unilever Plc. (GB) 2014-10-15 EP disclosed
US-20140295010-A1 SKIN ANTI-AGEING COMPOSITION CONOPCO, INC. D/B/A UNILEVER (US) 2014-10-02 US disclosed
WO-2003030857-A1 ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN UNILEVER PLC (GB) 2003-04-17 WO disclosed
EP-0350488-B1 1,2-DEHYDROGENATION OF STEROIDAL 21-ESTERS WITH A. SIMPLEX THE UPJOHN COMPANY (US) 1993-09-08 EP disclosed
US-5225335-A Enzymatic dehydrogenation THE UPJOHN COMPANY (US) 1993-07-06 US disclosed
US-4749649-A Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen THE UPJOHN COMPANY (US) 1988-06-07 US disclosed
US-4704358-A Δ1 -dehydrogenation with heat or air-dried B. cyclooxidans THE UPJOHN COMPANY (US) 1987-11-03 US disclosed
EP-0127294-A1 Steroid dehydrogenation THE UPJOHN COMPANY (US) 1984-12-05 EP disclosed
US-4189430-A Epoxide process THE UPJOHN COMPANY (US) 1980-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124159-A1 Enhancing epidermal barrier development in skin NR1H2, NR1H3, RXRB HIF1A 538/4885NR3C2 471/4885SMN1; SMN2 4529/4885
US-10456344-B2 Hair composition GLS2, GLS, LHCGR HIF1A 2417/4885NR3C2 69/4885SMN1; SMN2 4563/4885
US-20170360673-A1 HAIR COMPOSITION GLS2, GLS, CYP17A1 HIF1A 2563/4885NR3C2 79/4885SMN1; SMN2 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.